Tag:
Astellas
Latest Headlines
Latest Headlines
INC Research to close another facility, laying off around 30
INC is facing another facility closure. Its clinical study unit in Morgantown, WV will be shut down, according to a story by The State Journal .
Astellas scores FDA panel nod for overactive bladder drug
Astellas is one step closer to building its blockbuster business in overactive bladder meds.
AZ commits $140M to cancer pact as it inks back-to-back deals
A day after AstraZeneca ( $AZN ) managed to raise fresh doubts about its ability to efficiently develop new therapies with twin setbacks in the clinic, the pharma company is back with a pair of new
UPDATED: Medivation shares skyrocket on positive PhIII prostate cancer data
Medivation is reporting a promising set of late-stage data for MDV3100 this morning, offering some hard proof that the drug compares favorably with the newly-approved Zytiga for improving overall
Astellas shelves PhIII clot drug as rival blockbusters crowd market
Just weeks after unveiling some troubling mid-stage data on the risk of bleeding among patients with acute coronary syndrome, Astellas has decided to kill off its late-stage program for the
Bleeding risk spikes for Astellas's PhII anticoagulant
Just days after Pfizer ( $PFE ) and Bristol-Myers Squibb ( $BMY ) offered up stellar safety and efficacy data on their anti-clotting therapy Eliquis, researchers revealed that Astellas's oral
Merck snags Astellas' U.S. rights to IV vernakalant
Shares of Cardiome Pharma spiked 30% on Tuesday evening as news spread that Merck snapped up the U.S. rights Astellas had held for the IV formulation of vernakalant , a treatment for acute atrial
Astellas licenses Vical vax for $130M
Japan's Astellas will pay up to $130 million to license a vaccine to prevent cytomegalovirus (CMV) reactivation in transplant recipients. The disease is typically dormant in those who are healthy but
LifeCycle shares soar after low-dose organ rejection drug edges Prograf in Ph3
In a head-to-head study with a market leading treatment designed to prevent kidney transplant rejection, Denmark's LifeCycle Pharma says that its once-daily experimental drug edged out Astellas's
Astellas buys out Maxygen stake in JV for $76M
Astellas Pharma has exercised a buy-out option to acquire all of Maxygen's ownership interest in Perseid Therapeutics, a protein joint venture between the two companies. They formed the JV back in
